Axonics Announces $20.5 Million Second Closing of its Series C Financing

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash.

Global Surgical Lasers Market to Reach $10.1 Billion by 2027

1 Billion by 2027, growing at a CAGR of 9.7% over the analysis period 2020-2027. Solid-State Laser Systems, one of the segments analyzed in the report, is projected to record a 9.2% CAGR and reach US$3.9 Billion by the end of the analysis period.

Carestream Health Advances X-ray Image Quality with Smart Noise Cancellation

SNC has received FDA 510(k) Clearance and is available as an optional feature with Carestream’s ImageView Software powered by Eclipse—the intelligent image-processing engine behind the company’s innovative imaging software—on DRX-Evolution and DRX-Evolution Plus systems.

Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that it has completed a $20.5 million second closing of its Series C financing, bringing the total amount of capital raised for its Series C to $35 million.

The second closing of the Series C round included two new investors, Gilde Healthcare, which has offices in Boston and Utrecht, Netherlands, and CICA, Inc. based in La Jolla, California. Existing investor, Boston-based Cormorant Asset Management also participated in both closings as did a select group of private individuals.

Geoff Pardo, Partner at Gilde Healthcare, joined the Axonics board of directors. Pardo has significant experience in the medical device industry as an operator and venture investor.

Pardo commented, “Gilde believes that the SNM market will grow to over $1 billion in revenue in the next few years and with only one player in the market today, we are confident that Axonics, given the quality of its management team and its miniaturized implantable rechargeable system, is poised to take a measurable portion of that market following FDA approval.”

Proceeds from the financing will be used to conduct a pivotal clinical study in Overactive Bladder patients to gain U.S. FDA approval and prepare Axonics to access markets around the world. The U.S. pivotal study is anticipated to begin in late 2017 in select medical centers in North America and Europe. During 2016, the Axonics r-SNM system gained regulatory approval in Europe and Canada.

“On behalf of all the stakeholders in Axonics, we extend a warm welcome to our new world-class investors and Mr. Pardo as a new board member. The fact that this financing was oversubscribed is testament to the quality of work that the Company has done to create an innovative and highly competitive sacral neuromodulation system,” said Raymond W. Cohen, Chief Executive Officer of Axonics.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles